Hanem Sadek

Hanem Sadek

Auto-generated profile, based on publicly available information

Hanem Sadek

Human Lymphohaematopoiesis Laboratory, INSERM U1163, Paris, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
CLChantal Lagresle-Peyrou
Chantal Lagresle-Peyrou
SLSonia Luce
Sonia Luce
FOFarid Ouchani
Farid Ouchani
TSTayebeh Shabi Soheili
Tayebeh Shabi Soheili
HSHanem Sadek
Hanem Sadek
IAIsabelle André
Isabelle André

13 August 2015 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
ESE Six
E Six
CLChantal Lagresle-Peyrou
Chantal Lagresle-Peyrou
SSS Susini
S Susini
CCC De Chappedelaine
C De Chappedelaine
NSN Sigrist
N Sigrist
MCMarina Cavazzana
Marina Cavazzana
Reticular dysgenesis is a human severe combined immunodeficiency that is primarily characterized by profound neutropenia and lymphopenia. The condition is caused by mutations in the adenylate kinase 2 (AK2) gene, resulting in the loss of mitochondrial AK2 protein expression. AK2 regulates the homeostasis of mitochondrial adenine nucleotides (ADP, ATP and AMP) by catalyzing the transfer of high-energy phosphate. Our present results demonstrate that AK2-knocked-down progenitor cells have poor proliferative and survival capacities and are blocked in their differentiation toward lymphoid and granulocyte lineages. We also observed that AK2 deficiency impaired mitochondrial function in general and oxidative phosphorylation in particular – showing that AK2 is critical in the control of energy metabolism. Loss of AK2 disrupts this regulation and leads to a profound block in lymphoid and myeloid cell differentiation.

1 July 2014 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
CLChantal Lagresle-Peyrou
Chantal Lagresle-Peyrou
MMMichèle Millili
Michèle Millili
SLSonia Luce
Sonia Luce
ABAnnie Boned
Annie Boned
HSHanem Sadek
Hanem Sadek
CSClaudine Schiff
Claudine Schiff

21 December 2017 in Blood Advances
Verified
Journal Article
Closed access
PDF file
TSTayebeh Soheili
Tayebeh Soheili
ADAmandine Durand
Amandine Durand
FSFernando E. Sepulveda
Fernando E. Sepulveda
JRJulie Rivière
Julie Rivière
CLChantal Lagresle-Peyrou
Chantal Lagresle-Peyrou
IAIsabelle André
Isabelle André
Patients with mutations in the UNC13D gene (coding for Munc13-4 protein) suffer from familial hemophagocytic lymphohistiocytosis type 3 (FHL3), a life-threatening immune and hyperinflammatory disorder. The only curative treatment is allogeneic hematopoietic stem cell (HSC) transplantation, although the posttreatment survival rate is not satisfactory. Here, we demonstrate the curative potential of UNC13D gene correction of HSCs in a murine model of FHL3. We generated a self-inactivating lentiviral vector, used it to complement HSCs from Unc13d-deficient (Jinx) mice, and transplanted the cells back into the irradiated Jinx recipients. This procedure led to complete reconstitution of the immune system (ie, to wild-type levels). The recipients were then challenged with lymphocytic choriomeningitis virus to induce hemophagocytic lymphohistiocytosis (HLH)–like manifestations. All the clinical and biological signs of HLH were significantly reduced in mice having undergone HSC UNC13D gene correction than in nontreated animals. This beneficial effect was evidenced by the correction of blood cytopenia, body weight gain, normalization of the body temperature, decreased serum interferon-γ level, recovery of liver damage, and decreased viral load. These improvements can be explained by the restoration of the CD8+ T lymphocytes’ cytotoxic function (as demonstrated here in an in vitro degranulation assay). Overall, our results demonstrate the efficacy of HSC gene therapy in an FHL-like setting of immune dysregulation. Key Points UNC13D gene transfer into HSCs corrects all clinical and biological signs of HLH in a mouse model. Munc13-4 is expressed in mature CD8+ T cells allowing the correction of cytotoxic activity and consequently efficient viral restriction. Visual Abstract

1 May 2016 in Molecular Therapy
Verified
Journal Article
Open access
CLChantal Lagresle-Peyrou
Chantal Lagresle-Peyrou
CRCécile Roudaut
Cécile Roudaut
AGAurélie Gabrion
Aurélie Gabrion
LCLaure Caccavelli
Laure Caccavelli
HSHanem Sadek
Hanem Sadek
IAIsabelle André
Isabelle André